ASX Share rice
Thu 13 May 2021 - 01:42:pm (Sydney)

GCI Share Price

GRYPHON CAPITAL INCOME TRUSTGCINot Applic

GCI Company Information

Name:

Gryphon Capital Income Trust

Sector:

Financial

Industry:

Asset Management

Address:

Level 1 Brisbane QLD Australia 4006

GCI Share Price Information

Shares Issued:

206.13M

Market Capitalisation:

$411.22M

Dividend per Share:

$0.09

Ex Dividend Date:

2021-04-29

Dividend Yield:

4.51%

Earnings per Share:

$0.0642

GCI CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-5,129,000

Total Cashflow From Investing Activities:

$-5,129,000

Net Income:

$13.24M

Total Cash From Operating Activities:

$-192,226,000

Other Cashflow From Investing Activities:

$-5,129,000

Dividends Paid:

$-14,768,000

Sale Purchase Of Stock:

$225.65M

Capital Expenditures:

$0

GCI Income Statement

Income Date:

2020-06-30

Income Before Tax:

$13.24M

Net Income:

$13.24M

Gross Profit:

$13.77M

Operating Income:

$13.24M

Total Revenue:

$16.50M

Cost Of Revenue:

$2.73M

GCI Balance Sheet

Balance Sheet Date:

2020-06-30

Total Liabilities:

$1.73M

Total Stockholder Equity:

$411.04M

Total Assets:

$412.77M

Cash:

$13.20M

Net Receivables:

$0.97M

Accounts Payable:

$258K

GCI Share Price History

GCI News

05 Mar, 2021
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present at the following upcoming virtual conferences in March:
02 Mar, 2021
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 4,375,000 American Depositary Shares (ADSs) of the Company, at a price to the public of $8.00 per ADS, less underwriting discounts and commissions. Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company. The closing of the offering is expected to occur on or about March 4, 2021, subject to satisfaction of customary closing conditions.
23 Feb, 2021
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its plans to expand the Company's global Phase 2/3 study of opaganib[1] in patients with severe COVID-19 to the U.S., following U.S. Food and Drug Administration (FDA) review of the data from the U.S. Phase 2 study of opaganib and receipt of its recommendations.

GCI Dividend Payments

EX-Date Dividend Amount
2018-06-28$0.0046
2018-07-30$0.0048
2018-08-30$0.0062
2018-10-30$0.0088
2018-11-29$0.0086
2018-12-28$0.0088
2019-01-30$0.0088
2019-03-28$0.0089
2019-04-29$0.0084
2019-05-30$0.0087
2019-06-27$0.0085
2019-07-30$0.0084
2019-08-29$0.0077
2019-09-27$0.0076
2019-10-30$0.0076
2019-11-28$0.0070
2019-12-30$0.0073
2020-01-30$0.0073
2020-02-27$0.0068
2020-03-30$0.0071
2020-04-29$0.0065
2020-05-28$0.0065
2020-06-29$0.0067
2020-07-30$0.0072
2020-08-28$0.0072
2020-09-29$0.0071
2020-10-29$0.0074
2020-11-27$0.0071
2020-12-30$0.0072
2021-01-28$0.0075
2021-02-25$0.0068
2021-03-30$0.0075
2021-04-29$0.0073

GCI Dividends (last 4 Years)